Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.77 Analyst target: $9.00 Upside: 224.91%
Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing drugs for patients living with autoimmune diseases and amyotrophic lateral sclerosis (ALS) who require organ or cell transplantation. The company is headquartered in Irvine, California.
See the full interactive analysis & chart →Informational only — not investment advice.